Behling, Cynthia

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 10,791

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,146

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1,005

Association of histologic disease activity with progression of nonalcoholic fatty liver disease

Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 372

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 368

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

Ajmera, V., Cepin, S., Tesfai, K., Hofflich, H., Cadman, K., Lopez, S., Madamba, E., Bettencourt, R., Richards, L., Behling, C., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 327

Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease

Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 298

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 276

Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage

Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 272

Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease

Tamaki, N., Munaganuru, N., Jung, J., Yonan, A. Q., Loomba, R. R., Bettencourt, R., Ajmera, V., Valasek, M. A., Behling, C., Sirlin, C. B., et al. (2022) · Gut

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 130

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 110

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

Loomba, R., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Behling, C., Sirlin, C. B., Gottwald, M. D., Feng, S., et al. (2024) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 43